Health
Cancer Prevention
Female CEOs

Iovance Biotherapeutics

$19.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.25 (-1.25%) As of 2:28 PM EDT today
-$0.25 (-1.25%) Today

Why Robinhood?

You can buy or sell IOVA and other stocks, options, ETFs, and crypto commission-free!

About IOVA

Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. Read More The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Employees
88
Headquarters
San Carlos, California
Founded
2007
Market Cap
2.47B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.33M
High Today
$20.10
Low Today
$19.44
Open Price
$19.95
Volume
1.28M
52 Week High
$26.59
52 Week Low
$7.26

Collections

Health
Cancer Prevention
Female CEOs
Biotechnology
Medical
Therapy
Technology
2013 IPO

IOVA Earnings

-$0.38
-$0.34
-$0.31
-$0.27
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Oct 31, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.